Re: Endovascular Therapy for Erectile Dysfunction—Who Benefits Most? Insights from a Single-Center Experience

2019 ◽  
Vol 202 (3) ◽  
pp. 443-444
Author(s):  
Allen D. Seftel
2018 ◽  
Vol 15 (2) ◽  
pp. S67-S68
Author(s):  
E. Schommer ◽  
R. Pathak ◽  
Z. McNulty ◽  
R. Shah ◽  
G. Broderick

Urology ◽  
2009 ◽  
Vol 74 (4) ◽  
pp. S332
Author(s):  
M. Azémar ◽  
J. Ménard ◽  
T. Ripert ◽  
R. Messaoudi ◽  
F. Staerman

2019 ◽  
Vol 26 (2) ◽  
pp. 181-190 ◽  
Author(s):  
Nicolas Diehm ◽  
Stefanie Marggi ◽  
Yasushi Ueki ◽  
Dagmar Schumacher ◽  
Hak Hong Keo ◽  
...  

Purpose: To report the 1-year outcomes of a single-center, all-comers registry aimed to assess effectiveness and safety of endovascular revascularization for atherosclerotic erectile dysfunction (ED) in an unselected patient cohort. Materials and Methods: Between April 2016 and October 2017, 50 consecutive patients (mean age 59.6±10.3 years) underwent endovascular revascularization for ED owing to >50% stenosis in 82 erection-related arteries. Patients were treated by means of standard balloon angioplasty (16%), drug-coated balloon angioplasty (27%), or drug-eluting stent (55%) implantation. The primary feasibility outcome measure was the incidence of a minimum clinically relevant improvement of ≥4 in the 6-question International Index of Erectile Function Questionnaire (IIEF-6) score at 12 months. Clinical effectiveness was improvement in erectile function as quantified in the mean difference (MD) of the IIEF-15 score at 3 and 12 months as well as the mean changes in IIEF-15 questions 3 and 4. Results: Procedure success was achieved in 49 (98%) of 50 patients. At 12 months, 30 (65%) of 46 patients achieved a minimum clinically relevant improvement in the IIEF-6 score. The overall IIEF-15 score, as well as scores for questions 3 and 4, improved in 32 (65%) of 49 patients, 28 (57%) of 49 patients, and 29 (60%) of 48 patients, respectively. Change in the overall IIEF-15 score at 12 months was consistent among subgroups, except for elderly patients [MD −5.0 (95% CI −9.7 to −0.2), p=0.041] and those with hypertension [MD −11.0 (95% CI −20.5 to −1.5), p=0.025], who showed less improvement. Conclusion: Endovascular revascularization was safe and efficacious in the majority of ED patients through 1 year.


2021 ◽  
Author(s):  
Bjoern Simon ◽  
Jakob Neubauer ◽  
Martin Schoenthaler ◽  
Simon Hein ◽  
Fabian Bamberg ◽  
...  

Abstract Background Ureteroarterial fistula (UAF) is a rare but potentially life threatening disease. The aim of this study was to evaluate the outcome of endovascular therapy for UAF treatment.Methods This retrospective case series evaluates a single center experience of percutaneous stent graft angioplasty and/or coil embolization for UAF. Patient follow-up included technical and early clinical success, complications and revisional procedures. Results We identified 17 UAF in 16 consecutive patients (12 male, 4 female, mean age 69.8 ±11.3 years) who underwent endovascular UAF therapy at our tertiary hospital. All patients presented with hematuria. 5/17 presented with flank pain, in 7 of 17 cases patients were in hypovolemic shock. Risk factors of UAF included chronic indwelling ureteral stents in all fistulas, pelvic exstirpatory surgery in 13 cases. In 6 cases stent grafts were placed from the common iliac artery (CIA) to the external iliac artery (EIA) following coil embolization of the proximal internal iliac artery (IIA). Stent graft placement without previous coil embolization was performed in 10 fistulas. In one case only coil embolization of the IIA was performed. Mean follow-up was 654 (range: 1 – 3269) days. All procedures were technically successful and no procedure related deaths occurred during follow-up. During the initial hospital stay hematuria disappeared in 14/17 cases. Overall, four patients suffered recurrent hematuria, which in three cases resolved after a secondary intervention. One recurrent UAF related death occurred during follow-up 229 days after initial treatment.Conclusion Endovascular therapy proves to be a safe and efficient method in UAF treatment.Evidence-based medicineLevel 4, case series.


2021 ◽  
pp. 153857442110171
Author(s):  
Kunal Vani ◽  
Keith D. Calligaro ◽  
Krystal Maloni ◽  
Nicholas Madden ◽  
Douglas A. Troutman ◽  
...  

Objectives: Pancreaticoduodenal artery aneurysms (PDAAs) are rare and have a high propensity for rupture. Historically, management of PDAAs included surgical reconstruction but has evolved with advances in endovascular therapy. We report our experience with management of PDAAs during the last 30 years. Methods: We retrospectively reviewed our prospectively maintained registry between January 1, 1992 – March 30, 2020. Results: We identified 8 patients with PDAAs: 4 with associated celiac artery occlusive disease and 4 without identifiable etiologies. Four patients were treated with surgical resection of the PDAAs: 2 intact aneurysms underwent concomitant revascularization (superior mesenteric artery-to-hepatic artery Dacron bypass; supra celiac aorta-to-hepatic artery Dacron bypass) and 2 (1 intact, 1 rupture) underwent ligation alone. Four patients were treated with coil embolization of the PDAA: 2 with concomitant stent-graft exclusion of the aneurysm (1 non-rupture, 1 rupture) and 2 without adjunctive measures (intact). There were no deaths nor any significant procedure-related morbidity. Conclusion: Our large single-center experience shows that PDAAs can be successfully treated by open or endovascular intervention with selective revascularization.


Sign in / Sign up

Export Citation Format

Share Document